GranuFlo is a dry acid component of the blood cleansing mixture that is used by many commercial hemodialysis clinics. Dialysis is a process for cleaning the blood and eliminating the waste from the blood of people who have renal failure. Renal failure is the failure of the kidneys to clean the blood to eliminate waste from the blood.
Dialysis cleansing mixtures contain a combination of bicarbonate, acid, and purified water. Traditionally, the acid component was in liquid form and was delivered to dialysis clinics in drums. However, in an effort to save shipping costs Fresenius Medical Care, N.A. developed a dry powder acid for the mixture that was cheaper to ship. The dry acid was much more dangerous for patients but saved money for the commercial dialysis clinics.
There is no safety or health benefit to the patient for this new dry powder acid component. The new GranuFlo dry powder acid also contains sodium diacetate which is processed by the liver and increases the blood pH to dangerous levels.
The higher pH levels has been causing a rash of heart attacks, strokes, and blood clots in dialysis patients exposed to the GranuFlo product.
The FDA has evidence that Fresenius Medical Care knew about the dangers of GranuFlo and concealed them to avoid loss of sales. On May 25, 2012, the FDA issued a Class 1 Recall for Granuflo. If you or a loved one has suffered a heart attack, blood clot, stroke, or death after receiving dialysis you may have a claim for money compensation against the manufacturer.